Summarized by Masters of Longevity from Stevenage Bioscience Catalyst.
A short news article about a PET imaging biodistribution study of a lead neuroscience drug candidate, explaining what readers will learn about the trial’s purpose and design.
Key Takeaways
- NRG5051 has been radiolabelled and is now undergoing PET scans in volunteers.
- The PET trial will measure blood kinetics and calculate a brain distribution coefficient.
- Proving CNS penetration by PET will guide dose choice and support clinical plans.
